Intercept (ICPT) Bearish Concerns Tied to Trial Size; RBC Reiterates Outperform
Tweet Send to a Friend
RBC Capital reiterated an Outperform rating on Intercept Pharmaceuticals (NASDAQ: ICPT) with a price target of $490. Earlier Intercept announced ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
